Dianthus Therapeutics to present Phase 3 CAPTIVATE interim CIDP analysis of claseprubart at 2026 AANEM

The company said it will present a Phase 3 CAPTIVATE interim analysis of claseprubart in CIDP at the 2026 AANEM annual meeting, plus further updates on myasthenia gravis.